ABSTRACT: The goal of the Translation Accelerator Core is to provide the appropriate expertise and resources to advance the translational efforts of the Stanford AViDD Center projects with industry-level rigor. Embedded in the Core is an Industry Consultants Consortium that will provide expert support for all key facets of successful preclinical development—from lead identification, to lead optimization, to nomination of a development candidate, and appropriate IND-enabling studies. This preclinical development includes virtual small molecule screening, computational chemistry and modeling, medicinal chemistry, in vitro characterization of drug metabolism and pharmacokinetic (DMPK) properties, formulation, scale-up and process chemistry including analytical methods development, in vivo toxicology and characterization of drug metabolism and pharmacokinetic (DMPK) properties, and regulatory affairs. Finally, to ensure these efforts are efficient and maximally productive, we have assembled a trio of world-class directors of research from industry, and incorporated organizations and industry partners whose mission and resources are dedicated to helping compelling lead molecules advance towards commercialization. Successful accomplishment of this Core’s efforts will enable the development of new classes of outpatient antiviral therapeutics for SARS-CoV-2 and other RNA viruses of pandemic potential.